Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer

NICE technology appraisals [TA212] Published date:

NICE does not recommend bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for people with metastatic colorectal cancer.

Why has NICE said this?

NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life.

Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine does not provide enough benefit to patients to justify its high costs, and did not qualify for special consideration, so NICE did not recommend it.

Get involved